Welcome to our dedicated page for Tango Therapeutics news (Ticker: TNGX), a resource for investors and traders seeking the latest updates and insights on Tango Therapeutics stock.
Tango Therapeutics, Inc. reports developments as a clinical-stage biotechnology company focused on precision oncology. The company uses the genetic principle of synthetic lethality to discover and develop cancer therapies, with news centered on its PRMT5 inhibitor program, including vopimetostat, and related oncology combination research.
Recurring updates also cover financial results and business highlights, clinical supply and collaboration activity, investor-conference participation, board and executive appointments, and equity compensation actions under the company’s 2023 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
Tango Therapeutics, a biotechnology company focused on precision cancer medicines, announced participation in two virtual investor conferences in February 2022. The Guggenheim 2022 Oncology Conference is scheduled for February 9, 2022, at 9:00 AM ET, while the 11th Annual SVB Leerink Global Healthcare Conference will take place on February 16, 2022, at 1:00 PM ET. Live webcasts will be available under the 'Events & Presentations' section on the company’s website, with replays accessible for 30 days.
Tango Therapeutics, Inc. (NASDAQ: TNGX) announced the FDA's clearance of the IND for its lead program, TNG908, a selective PRMT5 inhibitor targeting cancers with MTAP deletions. The first-in-human clinical trial is expected to commence in 1H 2022, with preliminary data anticipated in 1H 2023. The company is also advancing its Target 3 program, aimed at reversing immune evasion in STK11 mutant cancers, and plans to develop a USP1 inhibitor for BRCA1-mutant cancers in 2H 2022. Tango’s cash balance is projected to fund operations into 2H 2024.
Tango Therapeutics (NASDAQ: TNGX) announced participation in the Jefferies London Healthcare Conference on November 18, 2021. The management team will present, with the session available on-demand starting at 8 AM GMT. A replay will be accessible for 30 days on the company's website. Tango focuses on precision cancer medicine, leveraging synthetic lethality to target cancer cells and enhance treatment efficacy. For more details, visit tangotx.com.
Tango Therapeutics (TNGX) reported a strong cash position of $504 million, ensuring funding for operations through 2024. The company is on track for an IND filing for TNG908, a PRMT5 inhibitor targeting cancers with MTAP deletion, expected in Q4 2021. Q3 2021 collaboration revenue rose to $6.8 million, a significant turnaround from a prior decline. R&D expenses increased to $21.9 million, while the net loss decreased to $19.6 million or $0.28 per share, down from $26.8 million previously.
Tango Therapeutics, Inc. (NASDAQ: TNGX) announced two senior management appointments on November 1, 2021. Marc Rudoltz, M.D., joins as Chief Medical Officer, bringing over 20 years of oncology clinical development experience. Doug Barry, J.D., has been appointed General Counsel, with over 20 years in corporate law. CEO Barbara Weber expressed confidence in their expertise, particularly as Tango advances TNG908, a PRMT5 inhibitor, into clinical trials in 2022. Tango focuses on precision cancer medicine, leveraging synthetic lethality for novel treatment targets.
Tango Therapeutics (NASDAQ: TNGX) announced five abstracts selected for presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics from October 7-10, 2021. The preclinical data emphasize the potential of synthetic lethal targeting in cancer treatment, particularly highlighting TNG908, a PRMT5 inhibitor showing significant regressions in MTAP-deleted cancers. Dr. Barbara Weber, CEO, will co-chair a session on synthetic lethality during the conference, underscoring Tango's commitment to advancing precision cancer therapies.
Tango Therapeutics has completed its business combination with BCTG Acquisition Corp., a special purpose acquisition company, with the combined company to be listed on the Nasdaq under the ticker TNGX. The transaction is expected to provide Tango with a substantial cash position of approximately $515 million, which includes $342 million in gross proceeds from the business combination. This funding will support Tango’s goal of developing precision oncology therapies, focusing on novel treatments for genetically-defined cancer patient populations.